Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: hepionpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2022 | $3.50 | Overweight | Cantor Fitzgerald |
425 - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
425 - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
425 - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
D - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
425 - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ("Pharma Two B"), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease ("PD") and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion"), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today jointly announced that the U.S. Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form F-4 (as amended, the "Registration Statement") filed
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ("Pharma Two B"), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease ("PD") and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion"), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The
Pharma Two B Ltd. ("Pharma Two B") has entered into a merger agreement with Hepion Pharmaceuticals, Inc. ("Hepion") (NASDAQ:HEPA)Immediately upon completion of the merger, current Pharma Two B equity-holders will own approximately 85% of the combined company and current Hepion equity-holders will own approximately 15% of the combined company, in each case on a pro forma basis, subject to certain adjustments set forth in the merger agreement and prior to closing of the concurrent private financingImmediately upon closing of the $11.5 million concurrent private financing, current Pharma Two B equity-holders will own approximately 44.5% of the combined company, current Hepion equity-holders wil
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multi-center, double-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enro
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million. As part of this transaction, the
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah. Presentation Details Title: Hepatic Functional Improvement Detected by HepQuant DuO within 120 Days of Treatment with Rencofilstat in MASH Subject
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, N.J., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that its Board of Directors has approved a strategic restructuring pl
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston. Scott Campbell, PhD, Hepion's Quantitative Translational Pharmacologist, will deliver an oral presentation on the use of AI / machine learning ("ML") to enrich NASH clinical trials and for NASH patient
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023. Hepion is pleased to invite all interested parties to participate in a conference call at 8:30 a.m. ET on May 22, during which the ALTITUDE-NASH topline results will be discussed.
EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), announced today that its 2022 annual meeting of stockholders (the "Annual Meeting") has been further adjourned to Friday, August 5, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4 (Authorized Share Increase), as described in Hepion's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 29, 2022 (the "Proxy Statement"). T
EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that it expects to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial before the market opens on Monday, September 13, 2021. As previously disclosed, all primary endpoints were achieved in the trial. Hepion is pleased to invite all interested parties to participate in a conference call and webcast at 8:30 a.m. ET on September 13, during which the previously disclo
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p
TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o
EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med
EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), announced today that its 2022 annual meeting of stockholders (the "Annual Meeting") has been adjourned to Friday, July 22, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4 (Authorized Share Increase), as described in Hepion's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on April 19, 2022 (the "Proxy Statement"). The record
- Dr. Aspeslet joins the Company to support rencofilstat's clinical program - EDISON, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointment of Launa J. Aspeslet, PhD, RAC, as Chief Operating Officer. A versatile C-level executive with more than 25 years of progressive life sciences industry leadership and management experience, Dr. Aspeslet has expertise in strategic planning and growth; clinical researc
- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion's business development and partnering efforts in Asia - EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced that it has appointed Eddie C. Cheung, M.D., FACG, to lead Strategic Medical Affairs in Asia. In this newly created role with Hepion, Dr. Cheung will explore an
EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced the appointment of Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer ("CMO"), effective February 16, 2021. In this role, Dr. Hobbs will help lead Hepion's engagement with the U.S. Food and Drug Administration ("FDA"), global and national thought leaders, key policymakers, and professional associations. Dr. Hobbs joins Hepion from Novo Nordisk Inc., one o
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director. Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company's pre-clinical and clinical drug development programs and associated intellectual property. Dr. Thomas H. Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the Universit
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in development for Parkinson’s Disease. The merger is valued at an estimated pro-forma implied equity value of approximately $58.5 million. Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B. The combined company will continue to operate under the “Pharma Two B” name. Pharma Two B has agreed to file a registration statement with the SEC to register the ordinary shares proposed to be issued to Hepion’s equity holders in the acquisition.
RR: 100% | Richtech Robotics Celebrates Completion of Installation of ADAM at Ghost Kitchens inside Dawsonville, GA Walmart MIRA: 84% | MIRA Pharmaceuticals Announces New Preclinical Study Results Highlighting Potential Advantages Of Novel Oral Ketamine Analog Ketamir-2 For Neurological And Neuropsychiatric Disorders HEPA: 62% | Pharma Two B To Go Public Through Merger With Hepion Pharmaceuticals; Co. Also Announces $2.9M Private Placement Of Non-Convertible Senior Notes To Institutional Investors
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.02% to 38,373.22 while the NASDAQ rose 1.45% to 15,503.89. The S&P 500 also rose, gaining, 1.22% to 5,027.92. Check This Out: Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Leading and Lagging SectorsFinancial shares climbed by 1.3% on Monday. In trading on Monday, materials shares rose by just 0.2%. Top Headline Shares of Zions Bancorporation, N.A. (NASDAQ:ZION) gained around 4% on Monday after the company reported upbeat earnings for its first quarter. The company posted a first-quarter FY24 revenue decline of 11.6% year-
Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multicenter, double-blinded study with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized. Approximately 80 subjects have completed their Day 365 visits and are evaluated for safety and efficacy. An additional 40 subjects will provide significant safety data for evaluation. The
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock. Vaxxinity shares dipped 54.8% to $0.2150 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Matterport, Inc. (NASDAQ:MTTR) shares jumped 184% to $4.93. CoStar Group announced plans to acquire Matterport in a cash and stock transaction valued at $5.50 per share reflecting an estimated $1.6 billion value. NewGenIvf Group Limited (NASDAQ:NIVF) climbed 126% to $1.67 after the company signed a non-binding term sheet for a potential reverse merger with European Wellness Inv
Gainers NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Recovery (NASDAQ:LIFW) shares rose 29.74% to $1.23. The company's market cap stands at $19.5 million. Assure Hldgs (NASDAQ:IONM) stock increased by 24.31% to $0.55. The market value of their outstanding shares is at $4.9 million. ProKidney (NASDAQ:PROK) stock increased by 22.79% to $2.5. The company's market cap stands at $154.3 million. iSpecimen (NASDAQ:ISPC) shares increased by 19.32% to $0.34. The company's market cap stands at $3.1 million. GlucoTrack (NASDAQ:GCTK) stock moved upwards b
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.24% to 38,078.26 while the NASDAQ rose 0.25% to 15,320.07. The S&P 500 also rose, gaining, 0.29% to 4,981.79. Check This Out: Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Leading and Lagging Sectors Industrials shares climbed by 0.6% on Monday. In trading on Monday, communication services shares fell by 0.4%. Top HeadlineAlbertsons Companies Inc (NYSE:ACI) reported upbeat earnings for its fourth quarter. The company posted fourth-quarter FY23 sales growth of 0.4% year-on-year to $18.34 billion, missing the analyst c
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday. Following the market opening Monday, the Dow traded up 0.31% to 38,104.99 while the NASDAQ rose 0.62% to 15,376.02. The S&P 500 also rose, gaining, 0.40% to 4,987.10. Check This Out: Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Leading and Lagging Sectors Information technology shares climbed by 0.8% on Monday. In trading on Monday, energy shares fell by 0.4%. Top Headline The Chicago Fed National Activity Index increased to +0.15 in March versus a revised reading of +0.09 in the previous month, topping market estimates of +0.09. Equities Tradin